Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Burden of hospital-acquired SARS-CoV-2 infections in Germany: occurrence and outcomes of different variants

M. Bonsignore a,b, S. Hohenstein c, C. Kodde d,*, J. Leiner c, K. Schwegmann e, A. Bollmann c, R. Möller f, R. Kuhlen f, I. Nachtigall g,h

a Department of Infectiology and Infection Prevention, Helios Klinikum Duisburg, Duisburg, Germany
b Center for Clinical and Translational Research, Helios Universitätsklinikum Wuppertal, University of Witten/Herdecke, Wuppertal, Germany
c Heart Centre Leipzig at University of Leipzig and Helios Health Institute, Berlin, Germany
d Department of Pneumology, Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring, Berlin, Germany
e Central Department for Hygiene, Helios Kliniken, Hildesheim, Germany
f Helios Health Institute, Berlin, Germany
g Department of Infectious Diseases and Infection Prevention, HELIOS Hospital Emil-von-Behring, Berlin, Germany
h Charité – Universitätsmedizin Berlin, Institute of Hygiene and Environmental Medicine, Berlin, Germany

ARTICLE INFO

Article history:
Received 21 July 2022
Accepted 4 August 2022
Available online 20 August 2022

Keywords:
Hospital-acquired infection
COVID-19
SARS-CoV-2
SARI
Variants

SUMMARY

Background: Avoiding in-hospital transmissions has been crucial in the COVID-19 pandemic. Little is known on the extent to which hospital-acquired SARS-CoV-2 variants have caused infections in Germany.

Aim: To analyse the occurrence and the outcomes of HAI with regard to different SARS-CoV-2 variants.

Methods: Patients with SARS-CoV-2 infections hospitalized between March 1st, 2020 and May 17th, 2022 in 79 hospitals of the Helios Group were included. Information on patients’ characteristics and outcomes were retrieved from claims data. In accordance with the Robert Koch Institute, infections were classified as hospital-acquired when tested positive >6 days after admission and if no information hinted at a different source.

Findings: In all, 62,875 SARS-CoV-2 patients were analysed, of whom 10.6% had HAI. HAIs represented 14.7% of SARS-CoV-2 inpatients during the Wildtype period, 3.5% during Alpha (odds ratio: 0.21; 95% confidence interval: 0.19 to 0.24), 8.8% during Delta (2.70; 2.35 to 3.09) and 10.1% during Omicron (1.10; 1.03 to 1.19). When age and comorbidities were accounted for, HAI had lower odds for death than community-acquired infections (0.802; 0.740 to 0.866). Compared to the Wildtype period, HAIs during Omicron were associated with lower odds for ICU (0.78; 0.69 to 0.88), ventilation (0.47; 0.39 to 0.56), and death (0.33; 0.28 to 0.40).

Conclusion: Hospital-acquired SARS-CoV-2 infections occurred throughout the pandemic, affecting highly vulnerable patients. Although transmissibility increased with newer variants, the proportion of HAIs decreased, indicating improved infection prevention and/or
the effect of immunization. Furthermore, the Omicron period was associated with improved outcomes. However, the burden of hospital-acquired SARS-CoV-2 infections remains high.

© 2022 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.

Introduction

When the novel SARS-CoV-2 started spreading throughout the world, its high transmissibility soon became apparent. Under unfavourable conditions, a single person was able to infect many others, causing so-called super-spreader events and outbreaks in different settings. This posed major challenges for hospitals to prevent nosocomial spread. Initially, knowledge about the disease and its transmission routes was scarce; this led to a wide variety of prevention measures being employed, including some that now seem superfluous, such as the use of coveralls or thermographic cameras or even setting up separate hospitals for the treatment of COVID-19 patients. At the beginning of the pandemic, there was broad consensus among the scientific community that the transmission occurred mainly via droplets, as in other respiratory viruses and in rare cases via other body fluids or indirectly via surfaces [1]. The focus of prevention measures rested therefore on separation and isolation, the use of surgical masks, face shields, protective gowns, frequent handwashing and enhanced environment disinfection protocols [2,3]. Increasing evidence of super-spreader events with transmissions among persons without direct contact and over significant distances made the airborne route appear increasingly plausible [4,5]. This shifted the emphasis on measures such as masks with higher filtration capability (FFP2 or KN95 masks) and towards improving indoor air using frequent ventilation and filtration.

Despite an increasing understanding of the infection, its transmission mechanisms and the corresponding tailoring of precautions, outbreaks have continued to occur throughout the pandemic in care facilities and hospitals. Little is yet known about the total burden of these infections in Germany during the pandemic. This study analyses the occurrence and the outcomes of hospital-acquired SARS-CoV-2 infections within a large hospital group, as well as the influence of virus variants.

Methods

This study is a retrospective analysis based on claims and surveillance data. We included all inpatients hospitalized with the International Classification of Diseases (ICD-10) code U07.1 (polymerase chain reaction (PCR)-confirmed SARS-CoV-2 infection) as main or secondary diagnosis in 79 hospitals of the Helios Group between March 1st, 2020 and May 17th, 2022. Helios is a privately owned company with hospitals spread throughout Germany. Its proportion of basic to tertiary care is comparable to the overall distribution of hospitals in the country, treatment in Helios hospitals being covered by all German health insurances. Patients from the claims data retrieval were linked to patients documented in the INOK database, this being a Helios’ own, group-wide, intranet-based surveillance programme, in which trained infection control nurses document daily new patients with a SARS-CoV-2 infection. In accordance with the criteria of the Robert Koch Institute, infections were classified as being hospital-acquired as follows:

- Positive SARS-CoV-2 PCR after day 6 of the inpatient stay and no other obvious source of infection, e.g. previously infected household members or visitors;
- Positive SARS-CoV-2 PCR on day 3–6 of hospital stay and strong suspicion of transmission in hospital;
- Readmission of a patient with a positive SARS-CoV-2 PCR ≤6 days after discharge and strong suspicion of transmission in hospital [6].

Claims and surveillance data were linked by a double-pseudonymized case number.

Information on sex, age, comorbidities, treatment in an intensive care unit (ICU), mechanical ventilation, and death were retrieved from claims data. Mechanical ventilation was defined as ventilation with pressure support via either invasive devices such as tracheal tube or tracheostomy, or use of non-invasive devices. Mortality was defined as death during the same hospital stay. Cases with discharge due to hospital transfer were excluded from the calculation of the mortality rate. Claims data on comorbidity was summarized by the Elixhauser Comorbidity Index, a score for categorizing patient comorbidities based on ICD-10 codes [7]. As surrogate parameter for the number of patients with symptoms among those infected with SARS-CoV-2, the documentation of a severe acute respiratory infection (SARI) was included, as defined by the ICD-10-codes J09-J22 according to the method of SARI surveillance [8].

For further analysis, each patient was associated with the variant that was prevalent at the time of becoming infected. Actual results of variant analyses were not available. The time-period of predominance of each variant was derived from the weekly reports of the Robert Koch Institute on variant development in Germany as follows:

(1) Wild type period: February 4th, 2020 to March 7th, 2021
(2) Alpha period: March 8th, 2021 to June 25th, 2021
(3) Delta period: June 26th, 2021 to January 2nd, 2022
(4) Omicron period: January 3rd, 2022 to present [9].

Statistics

Inferential statistics were based on generalized linear mixed models (GLMMs) specifying hospitals as random factor [10]. Effects were estimated with the lme 4 package (version 1.1–26) in the R environment for statistical computing (version 4.0.2, 64-bit build) [11,12]. For all tests a two-tailed 5% error criterion for significance was applied. For the description of the patient characteristics of the cohorts, χ²-tests were employed for binary variables and analysis of variance for numeric variables. Proportions, means, standard deviations, and P-values are reported.
For the comparison of outcomes, logistic GLMMs with logit link function were used. Proportions, odds ratios together with confidence intervals and P-values are reported.

Logistic GLMMs were used for multivariable analysis of binary outcomes. The analysis of weekly HAIs proportions was done via beta regression. Numerical predictors were centred on their mean and scaled to unit variance.

Statistics for Elixhauser Comorbidity Index are reported. For this index, the Agency for Healthcare Research and Quality (AHRQ) algorithm was applied [13].

**Ethics**

The local ethics Committee (vote: AZ490/20-ek) and Helios Kliniken GmbH data protection authority approved data use for this study.

### Table I

| Variant/variable | Community-acquired infection (CAI) | Hospital-acquired infection (HAI) | OR (95% CI) HAI vs CAI | P-value |
|------------------|-----------------------------------|----------------------------------|------------------------|---------|
| All              | 56,223                            | 6652 (10.6%)                     | n/a                    | n/a     |
| Age (years)      | 62.5 ± 22.8                       | 72.5 ± 17.0                     | n/a                    | <0.01   |
| Gender           | 28,625 (50.9%)                    | 3415 (51.3%)                    | n/a                    | ns      |
| ECI              | 8.8 ± 10.7                        | 15.8 ± 13.7                     | n/a                    | <0.01   |
| SARI             | 31,918 (56.8%)                    | 2794 (42.0%)                    | 0.57 (0.54–0.60)       | <0.001  |
| ICU              | 11,581 (20.6%)                    | 2305 (34.7%)                    | 1.99 (1.88–2.11)       | <0.001  |
| Mechanical ventilation | 7727 (13.7%)  | 892 (13.4%)                     | 0.92 (0.85–0.99)       | 0.032   |
| Mortality        | 7228 (14.5%)                      | 1234 (20.9%)                    | 1.53 (1.43–1.64)       | <0.001  |
| Wildtype         | 18,299                            | 3,143 (14.7%)                   | n/a                    | n/a     |
| Age (years)      | 67.9 ± 19.3                       | 73.7 ± 15.3                     | n/a                    | <0.01   |
| Gender           | 9,396 (51.3%)                     | 1,560 (49.6%)                   | n/a                    | ns      |
| ECI              | 10.4 ± 11.1                       | 16.8 ± 13.4                     | n/a                    | <0.01   |
| SARI             | 13,173 (72.0%)                    | 1,721 (54.8%)                   | 0.48 (0.44–0.52)       | <0.001  |
| ICU              | 4,450 (24.3%)                     | 1,150 (36.6%)                   | 1.74 (1.60–1.89)       | <0.001  |
| Mechanical ventilation | 3,046 (16.6%) | 511 (16.3%)                      | 0.92 (0.81–1.02)       | ns      |
| Mortality        | 3,310 (20.2%)                     | 760 (27.9%)                     | 1.49 (1.35–1.63)       | <0.001  |
| Alpha            | 7.567                             | 274 (3.5%)                      | n/a                    | n/a     |
| Age (years)      | 61.0 ± 19.5                       | 71.1 ± 19.0                     | n/a                    | <0.01   |
| Gender           | 4,091 (54.1%)                     | 1,34 (48.9%)                    | n/a                    | ns      |
| ECI (mean ± SD)  | 8.7 ± 10.5                        | 15.2 ± 13.3                     | n/a                    | <0.01   |
| SARI             | 5,662 (74.8%)                     | 1,22 (44.5%)                    | 0.30 (0.23–0.40)       | <0.001  |
| ICU              | 2,005 (26.5%)                     | 90 (32.8%)                      | 1.53 (1.17–2.01)       | 0.002   |
| Mechanical ventilation | 1,610 (21.3%) | 44 (16.1%)                       | 0.76 (0.54–1.06)       | ns      |
| Mortality        | 957 (14.1%)                       | 50 (20.4%)                      | 1.65 (1.18–2.30)       | 0.003   |
| Delta            | 11.285                            | 1.085 (8.8%)                    | n/a                    | n/a     |
| Age (years)      | 60.9 ± 22.5                       | 69.4 ± 19.3                     | n/a                    | <0.01   |
| Gender           | 5,921 (52.5%)                     | 586 (54.0%)                     | n/a                    | ns      |
| ECI (mean ± SD)  | 8.7 ± 10.5                        | 15.7 ± 14.8                     | n/a                    | <0.01   |
| SARI             | 7,340 (65.0%)                     | 406 (37.4%)                     | 0.38 (0.28–0.37)       | <0.001  |
| ICU              | 2,616 (23.2%)                     | 375 (34.6%)                     | 1.72 (1.49–1.98)       | <0.001  |
| Mechanical ventilation | 2,068 (18.3%) | 151 (13.9%)                      | 0.69 (0.57–0.82)       | <0.001  |
| Mortality        | 1,676 (16.6%)                     | 201 (20.2%)                     | 1.24 (1.05–1.47)       | 0.012   |
| Omicron          | 19.072                            | 2,150 (10.1%)                   | n/a                    | <0.01   |
| Age (years)      | 58.9 ± 26.2                       | 72.5 ± 17.7                     | n/a                    | <0.01   |
| Gender           | 9,219 (48.4%)                     | 1135 (52.8%)                    | n/a                    | <0.01   |
| ECI (mean ± SD)  | 7.5 ± 10.3                        | 14.3 ± 13.5                     | n/a                    | <0.01   |
| SARI             | 5,743 (30.1%)                     | 545 (25.3%)                     | 0.77 (0.69–0.85)       | <0.001  |
| ICU              | 2,510 (13.2%)                     | 690 (32.1%)                     | 2.93 (2.64–3.35)       | <0.001  |
| Mechanical ventilation | 1,003 (5.3%) | 186 (8.7%)                       | 1.58 (1.33–1.86)       | <0.001  |
| Mortality        | 1,283 (7.7%)                      | 223 (11.4%)                     | 1.51 (1.30–1.76)       | <0.001  |

OR, odds ratio; CI, confidence interval; ECI, Elixhauser Comorbidity Index; SARI, severe acute respiratory infection; ICU, intensive care unit; SD, standard deviation; n/a, not applicable; ns, not significant.

### Results

**Occurrence of hospital-acquired SARS-CoV-2 infections**

In total, 62,875 patients with a PCR-confirmed SARS-CoV-2 infection were included. In 6652 (11.8%) of these, the infection was categorized as hospital-acquired (HAI) (Table I).

The number of HAIs varied during the pandemic. It peaked during the Wildtype period (208 HAIs per week) and Omicron period (229 HAIs per week) (Figure 1A). Generally, the number of HAIs increased with the number of community-acquired infections (CAIs) (odds ratio (OR): 2.871; 95% confidence interval (CI): 2.680–3.071; P < 0.001). However, the proportion of HAIs among all inpatients did not remain constant,
varying between zero and 31.2% (Figure 1B). There was no association between the proportion of HAIs and the number of CAIs, i.e. periods with a high number of inpatients with CAIs were neither associated with more nor with fewer transmissions (OR: 0.968; 95% CI: 0.830–1.123; \( P = 0.667 \)). Rather, the fluctuations in the proportions were determined by the variants. During the Wildtype period, the proportion of HAIs was highest, on average 14.7%; this decreased to 3.5% during Alpha (OR: 0.21; 95% CI: 0.19–0.24; \( P < 0.001 \)) and increased again to 8.8% during Delta (2.70; 2.35–3.09; \( P < 0.001 \)) and then to 10.1% during Omicron (1.10; 1.03–1.19; \( P = 0.015 \)).

**Outcomes of hospital-acquired SARS-CoV-2 infections**

Among patients with HAIs, 42.0% developed a severe acute respiratory infection (SARI), 34.7% were treated in ICU, 13.4% were ventilated, and 20.9% died (Table I). Compared to patients with CAIs, they were diagnosed less frequently with SARI (OR: 0.57; 95% CI: 0.54–0.60) and received less frequently mechanical ventilation (0.92; 0.85–0.99), but were treated more often in ICU (1.99; 1.88–2.12). Mortality was higher among patients with HAI (1.52; 1.43–1.64). However, patients with HAI were on average 10.0 years older and had an ECI 7.0 points higher (\( P < 0.01 \)) than patients with CAI. When age, sex, and ECI were controlled for (Table II, multivariable analyses), HAIs were associated with a higher risk for ICU (1.44; 1.35–1.53), but with a lower risk for ventilation (0.597; 0.55–0.65) and death (0.80; 0.74–0.87).

The outcomes of HAI differed between the various periods of variant dominance similarly to CAIs (Table I). ICU and mortality rates were highest during the Wildtype period (ICU: 36.6%, mortality: 27.9%). Outcomes became more favourable with each new variant. During the Omicron period, ICU rate fell to 32.1% and mortality rate to 11.4%. Compared to infections during the Wildtype period, HAIs during Omicron had the least odds for intensive care (OR: 0.78; 95% CI: 0.69–0.88; \( P < 0.001 \)), ventilation (0.47; 0.39–0.56; \( P < 0.001 \)), SARI (0.29; 0.25–0.33; \( P < 0.001 \)) and death (0.33; 0.28–0.40; \( P < 0.001 \)).

**Discussion**

In all, 62,875 patients treated with SARS-CoV-2 in the hospitals of the Helios group were analysed. Of these, around 11% had acquired the infection during the hospital stay. Earlier studies focusing on the first wave described proportions of HAIs of 12% in Wuhan and of 15–20% in England [14–18]. On the other hand, a single centre study from Boston detected only one HAI among nearly 10,000 inpatients during the first weeks of the pandemic [19].

To estimate the total occurrence of HAIs in Germany, the number of patients hospitalized since the beginning would be needed. However, due to incomplete reporting, the exact number is not known. Based on the total number of infections in the population and on the proportion of hospitalizations among the available reports, it can be roughly estimated that
about 915,000 COVID-19 patients have been hospitalized since the beginning of the pandemic and until April 2022 [9]. Assuming a similar burden of HAIs in all hospitals in Germany, up to 110,000 patients might have been affected by hospital-acquired SARS-CoV-2 infections in Germany since the beginning of the pandemic.

HAIs have occurred despite comprehensive infection control programmes. The hospital architecture in Germany is far from ideal regarding infections with an airborne transmission route: most rooms are designed to accommodate two or three patients and mechanically ventilated rooms are usual only in units for intensive care or stem cell transplants. A major problem is a low nurse-to-patient ratio. Germany introduced a law regulating this ratio only in 2019 and suspended it during months of 2021 on healthcare workers and persons at risk, Germany since beginning of the pandemic. This would correlate the number of people to whom an infected person will pass the virus in a totally naive population and in the absence of preventive measures) of around 2−3 [30,31]. R0 reached 4−5 with the Alpha variant, 5−8 with Delta, and 9−10 with Omicron [32−34]. The major decrease in the proportion of HAIs during Alpha can probably be attributed to improvements in preventive measures and in outbreak management, but above all to the vaccination campaign, which focused during the first months of 2021 on healthcare workers and persons at risk, providing initially a high level of protection against the infection. The later rebound is probably the consequence of the increase in transmissibility associated with Delta and Omicron.

### Outcome of hospital-acquired SARS-CoV-2 infections

Twenty-one percent of patients with HAI died in association with it. Extrapolated to the estimated number of hospitalized patients with SARS-CoV-2, up to 23,000 might have died in connection with a hospital-acquired SARS-CoV-2 infection in Germany since beginning of the pandemic. This would correspond to the order of magnitude of fatalities anticipated to result in the same period from all other common HAIs combined, such as surgical site infections, pneumonia, and urinary tract infections, including those caused by multidrug-resistant organisms [35].

However, not all deaths of patients with a hospital-acquired SARS-CoV-2 infection will have been caused directly by the infection. When the risk factors for an adverse outcome — age, gender and comorbidities — were accounted for, HAIs were associated with lower odds for death than CAIs. Furthermore, patients with HAI were less likely to be diagnosed with a severe respiratory infection. Both features indicate that there might have been a greater proportion among patients with HAI than among those with CAI, in whom the infection was a secondary if not incidental finding, perhaps detected in the course of routine testing and with no greater clinical relevance. These patients likely had other reasons for being hospitalized than a SARS-CoV-2 infection, leading to intensive care, mechanical ventilation, and death independently from a SARS-CoV-2 infection.

The Omicron period was associated with a significantly more favourable disease course. This is concordant to other studies comparing the outcome of Omicron to earlier variants [36,37]. In addition to an attenuated virulence of the coronavirus, this

### Table II

Multivariable analyses of risk factors for intensive care, mechanical ventilation and mortality, among all inpatients with SARS-CoV-2

| Variable                          | Intensive care | Mechanical ventilation | Mortality |
|-----------------------------------|---------------|------------------------|-----------|
|                                   | OR (95% CI)   | P-value                | OR (95% CI) | P-value | OR (95% CI) | P-value |
| Male sex                          | 1.627 (1.560−1.695) | <0.001 | 1.834 (1.740–1.928) | <0.001 | 1.620 (1.540–1.708) | <0.001 |
| Age                               | 1.038 (1.010–1.064) | 0.004 | 0.961 (0.930–0.991) | 0.010 | 1.057 (1.050–1.059) | <0.001 |
| Elixauser Comorbidity Index       | 1.814 (1.770–1.854) | <0.001 | 1.940 (1.890–1.990) | <0.001 | 1.057 (1.050–1.059) | <0.001 |
| Hospital - vs community-acquired  | 1.439 (1.350–1.530) | <0.001 | 0.597 (0.550–0.649) | <0.001 | 0.802 (0.740–0.866) | <0.001 |
| Alpha vs Wildtype                 | 1.290 (1.210–1.375) | <0.001 | 1.548 (1.440–1.661) | <0.001 | 0.914 (0.840–0.994) | 0.037 |
| Delta vs Wildtype                 | 1.054 (1.000–1.114) | 0.065 | 1.224 (1.150–1.303) | <0.001 | 1.007 (0.940–1.078) | ns |
| Omicron vs Wildtype               | 0.577 (0.550–0.608) | <0.001 | 0.323 (0.300–0.347) | <0.001 | 0.362 (0.340–0.388) | <0.001 |

OR, odds ratio; 95% CI, confidence interval; ns, not significant.
development is probably due to the increasing immunization of the population. Furthermore, during the Omicron period, only a quarter of the patients with HAI were diagnosed with a severe respiratory infection, indicating an increasing proportion of secondary findings. However, in spite of the decreasing relevance of HAIs and the more benign outcomes since the Omicron variant, the mortality rate of patients with HAI was still high.

**Strengths and limitations of the study**

To the best of our knowledge, this is the first study to analyze the occurrence and the outcome of hospital-acquired SARS-CoV-2 infections in a large cohort in Germany as well as to show the changes that came with new variants. However, there are limitations to the interpretation of the results.

The main parameter of the study — the classification of the infections into community-versus hospital-acquired — relies on an estimation. The criteria were set and all cases were evaluated individually, including patients’ history, laboratory, and imaging results in doubtful cases. Still, in some cases, the route of infection could not be traced with absolute certainty. The high number of infection control nurses involved probably caused a high inter-rater variability. The median incubation period of the early variants was 5 days, of Delta 4.3 and of Omicron 3 days [38–40]. Patients might have been infected in the first day(s) after admission and still tested positive before day 7, leading to the misclassification as CAs. Patients with disease manifestation after discharge were registered only when readmitted. On the other hand, ~25% of infections have an incubation period of more than seven days and some may therefore have been falsely allocated as hospital-acquired [38]. False-negative results in early stages of the disease or delayed testing, caused by limited access to testing early in the pandemic or by the lack of typical symptoms, will also have resulted in a misclassification into HAIs. As there was no universal and repetitive screening in the beginning of the pandemic, underreporting is probable.

In conclusion, the pandemic has represented an unprecedented challenge for healthcare workers and infection prevention and control teams in their efforts to avoid hospital spreading. In spite of extensive prevention measures, hospital-acquired SARS-CoV-2 infections have occurred since the beginning of the pandemic, affecting a highly vulnerable population group. Fortunately, although the transmissibility has increased with new variants, the proportion of HAIs has decreased, indicating an improvement in infection prevention. Furthermore, the Omicron period was associated with better outcomes. However, the burden of hospital-acquired SARS-CoV-2 infections remains high. Further research is urgently needed to define prevention measures adequate to lower this burden with the greatest benefit and least harm.

**Acknowledgements**

We would like to thank the infection control nurses of the Helios group, without whose immense commitment during the pandemic this study, among others, would not have been possible.

**Conflict of interest statement**

None declared.

**Funding sources**

None.

**References**

[1] World Health Organization. Getting your workplace ready for COVID-19. How COVID-19 spreads. Geneva: WHO; 2020.

[2] World Health Organization. Considerations for quarantine of individuals in the context of containment for coronavirus disease (COVID-19): interim guidance. Geneva: WHO; 2020.

[3] Lauritano D, Moreo G, Limongelli L, Hardone M, Carinci F. Environmental disinfection strategies to prevent indirect transmission of SARS-CoV2 in healthcare settings. Appl Sci 2020;10:6291.

[4] Prather KA, Marr LC, Schooley RT, McDermid MA, Wilson ME, Milton DK. Airborne transmission of SARS-CoV-2. Science 2020;370:303–4.

[5] Morawska L, Cao J. Airborne transmission of SARS-CoV-2: the world should face the reality. Environ Int 2020;139:105730.

[6] Robert-Koch-Institut. Durchführung einer Krankenhaus-Surveillance zur Erhebung von Daten zu Infektionen, Schweregrad und Todesfällen in Zusammenhang mit SARS-CoV-2 in Deutschland. 2021. Available at: https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/ Surveillanceprotokoll.pdf?__blob=publicationFile [last accessed June 2022].

[7] van Walraven C, Austin PC, Jennings A, Quan H, Forster AJ. A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data. Med Care 2009;47:626–33.

[8] Buda S, Tolksdorf K, Schuler E, Kuhlen R, Haas W. Establishing an ICD-10 code based SARI-surveillance in Germany — description of the system and first results from five recent influenza seasons. BMC Public Health 2017;17:1–13.

[9] Robert-Koch-Institut. Wöchentlicher Lagebericht des RKI zur Coronavirus-Krankheit-2019 (COVID-19). 31.03.2022. Available at: https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Wochenbericht/Wochenbericht_2022-03-31.pdf [last accessed April 2022].

[10] Baayen RH, Davidson DJ, Bates DM. Mixed-effects modeling with crossed random effects for subjects and items. J Memory Lang 2008;59:390–412.

[11] Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme 4. J Statist Softw 2015;67:1–48.

[12] R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available from: https://www.R-project.org/ [last accessed March 2022].

[13] Moore BJ, White S, Washington R, Coenen N, Elixhauser A. Identifying increased risk of readmission and in-hospital mortality using hospital administrative data: the AHRQ Elixhauser Comorbidity Index. Med Care 2017;55:698–705.

[14] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. J Am Med Assoc 2020;323:1061–9.

[15] Rickman HM, Rampling T, Shaw K, Martinez-Garcia G, Hall L, Coen P, et al. Nosocomial transmission of coronavirus disease 2019: a retrospective study of 66 hospital-acquired cases in a London teaching hospital. Clin Infect Dis 2021;72:690–3.

[16] Knight GM, Pham TM, Stimson J, Funk S, Jafari Y, Pople D, et al. The contribution of hospital-acquired infections to the COVID-19 epidemic in England in the first half of 2020. BMC Infect Dis 2022;22:1–14.

[17] Bhattacharya A, Collin SM, Stimson J, Theiwall S, Nsonwu O, Gerver S, et al. Healthcare-associated COVID-19 in England: a national data linkage study. J Infect 2021;83:565–72.

[18] Evans S, Agnew E, Vynnycky E, Stimson J, Bhattacharya A, Rooney C, et al. The impact of testing and infection prevention
and control strategies on within-hospital transmission dynamics of COVID-19 in English hospitals. Phil Trans R Soc B 2021;376:20200268.

[19] Rhee C, Baker M, Vaidya V, Tucker R, Resnick A, Morris CA, et al. Incidence of nosocomial COVID-19 in patients hospitalized at a large US academic medical center. JAMA Netw Open 2020;3:e202498.

[20] Aiken LH, Sermeus W, Van den Heede K, Sloane DM, Busse R, Mckee M, et al. Patient safety, satisfaction, and quality of hospital care: cross sectional surveys of nurses and patients in 12 countries in Europe and the United States. BMJ 2012;344:e1717.

[21] Schwab F, Meyer E, Geffers C, Gastmeier P. Understaffing, overcrowding, inappropriate nurse:ventilated patient ratio and nosocomial infections: which parameter is the best reflection of deficits? J Hosp Infect 2012;80:133–9.

[22] McHugh MD, Aiken LH, Sloane DM, Windsor C, Douglas C, Yates P. Effects of nurse-to-patient ratio legislation on nurse staffing and patient mortality, readmissions, and length of stay: a prospective study in a panel of hospitals. Lancet 2021;397:1905–13.

[23] Watson SI, Arulampalam W, Petrou S, Marlow N, Morgan AS, Draper ES, et al. The effects of a one-to-one nurse-to-patient ratio on the mortality rate in neonatal intensive care: a retrospective, longitudinal, population-based study. Arch Dis Child Fetal Neonatal Ed 2016;101:F195–200.

[24] Rossi R, Socci V, Pacitti F, Di Lorenzo G, Di Marco A, Siracusano A, et al. Mental health outcomes among frontline and second-line health care workers during the coronavirus disease 2019 (COVID-19) pandemic in Italy. JAMA Netw Open 2020;3:e2010185.

[25] Yildirim OA, Poyraz K, Erdur E. Depression and anxiety in cancer patients before and during the COVID-19 pandemic: association with treatment delays. Qual Life Res 2021;30:1903. –12.

[26] O’Hanlon S, Inouye SK. Delirium: a missing piece in the COVID-19 pandemic puzzle. Age Ageing 2020;49:497–8.

[27] Hophing M, Zimmerman-Winslow K-J, Basu A, Jacob T. The impact of COVID-19 and quarantine on suicidality in geriatric inpatients — a case report. J Geriat Psychiatry Neurol 2022;35:350–4.

[28] Fujita K, Ito T, Saito Z, Kanai O, Nakatani K, Mio T. Impact of COVID-19 pandemic on lung cancer treatment scheduling. Thorac Cancer 2020;11:2983–6.

[29] Our World in Data. Germany: coronavirus pandemic country profile. Available from: https://ourworldindata.org/coronavirus/country/germany [last accessed July 2022].

[30] Liu Y, Gayle AA, Wilder-Smith A, Rocklov J. The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Trav Med 2020;27(2):ttaa021.

[31] Alimohamadi Y, Taghdir M, Sepandi M. Estimate of the basic reproduction number for COVID-19: a systematic review and meta-analysis. J Prev Med Publ Health 2020;53:151.

[32] Hansen PR. Relative contagiousness of emerging virus variants: an analysis of the Alpha, Delta, and Omicron SARS-CoV-2 variants. Econometrica J 2022 March 24 [online].

[33] Liu Y, Rocklov J. The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus. J Travel Med 2021;28(7):taab124.

[34] Liu Y, Rocklov J. The effective reproductive number of the Omicron variant of SARS-CoV-2 is several times relative to Delta. J Travel Med 2022;29(3):taac037.

[35] Gastmeier P, Geffers C. Nosocomial infections in Germany. What are the numbers, based on the estimates for 2006? Deut Med Wochenschr 1946 2008;133:1111–5.

[36] Maslo C, Friedland R, Toubkin M, Labuscher A, Akaloo T, Kama B. Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 Omicron wave compared with previous waves. JAMA 2022;327:583–4.

[37] Bouzid D, Viseaux B, Kassassey C, Daoud A, Fémy F, Hermant C, et al. Comparison of patients infected with Delta versus Omicron COVID-19 variants presenting to Paris emergency departments: a retrospective cohort study. Ann Intern Med 2022;175:831–7.

[38] McAloon C, Collins A, Hunt K, Barber A, Byrne AW, Butler F, et al. Incubation period of COVID-19: a rapid systematic review and meta-analysis of observational research. BMJ Open 2020;10:e039652.

[39] Grant R, Charmet T, Schaeffer L, Galmiche S, Madec Y, Von Platen C, et al. Impact of SARS-CoV-2 Delta variant on incubation, transmission settings and vaccine effectiveness: results from a nationwide case–control study in France. Lancet Reg Health Eur 2022;13:100278.

[40] Brandal LT, MacDonald E, Veneti L, Ravlo T, Lange H, Naseer U, et al. Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021. Eurosurveillance 2021;26:2101147.